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1.1. Definition of tuberculosis 
 
Tuberculosis (TB) is one of the oldest diseases that affects humans, caused by the 
bacteria of Mycobacterium tuberculosis complex. Most commonly it affects the lungs 
(pulmonary tuberculosis), but other organs can be also affected (extrapulmonary 
tuberculosis). Tuberculosis that is caused by strains susceptible to drugs is mostly curable if 
treatment is started on time and if drugs are correctly chosen. If it is not treated, it may be 
fatal within 5 years in 50-65% of cases (1). 
 
1.2. Brief history of tuberculosis 
	
It is not exactly clear when tuberculosis first appeared. One study from 2008 reported 
that tuberculosis infection was present already about 9000 years ago (2).  
 Around 460 BCE, the father of modern medicine, Hippocrates, recognized and 
described the disease called phthisis, the Greek term for tuberculosis, as the most widespread 
disease of the time. He believed that tuberculosis is hereditary in nature.  
The greatest epidemics across Europe were occurring during the 18th and 19th 
centuries. In 1882 Robert Koch isolated the agent causing tuberculosis for the first time and 
one year later he named it Mycobacterium tuberculosis. The disease outcomes were 
detrimental - about a third of patients died within 1 year of diagnosis, and over half died 
within 5 years. The 5-year mortality rate among sputum smear-positive cases was 65%. Of 
the survivors at 5 years, 60% had undergone spontaneous remission, while the remainders 
were still excreting tubercle bacilli (1). Without treatment and cure, the isolation of the sick 
people inside the sanatoriums and away from the other population was the main method of 
preventing the spread of the disease.  
Another problem that doctors were facing was a lack of diagnostic tests that would 
show a presence of Mycobacterium tuberculosis. Discovery of x-rays in 1895 by Wilheld 
Konrady von Rontgen allowed doctors to assess the disease severity, extent and progression 
of this disease.  
Albert Calmette and Camille Guerin discovered the vaccine called BCG (Bacille 
Calmette- Guerin) in the beginning of the 20th century. This vaccine soon came to be widely 
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used. Schatz, Bugie and Waksman introduced the Streptomycin in 1944, the first drug and 
antibiotic that was truly effective against Mycobacterium Tuberculosis. Seven years later, the 
first mycobacterial drug Isoniazid was introduced and later on also some other (rifampicin). 
Those drugs were a huge success in the treatment of tuberculosis and the number of sick 
people drastically declined.  
1.3. Morphology  and charactersitics of Mycobacteria  
 
Mycobacteria are aerobic, rod-shaped non spore-forming bacteria. They do not stain 
easily, but after being stained, they resist decolourization by acid or alcohol. Because of that 
they are called “acid-fast” bacilli. For identification of acid- fast bacteria Ziehl- Neelsen 
staining technique is used (3).  
Three main groups of Mycobacteria are known: first one is Mycobacterium 
tuberculosis complex that includes Mycobacterium tuberculosis, Mycobacterium bovis, 
Mycobacterium africanum, Mycobacterium microti, and Mycobacterium canetti. Majority of 
tuberculosis in humans is caused by Mycobacterium tuberculosis. Other organisms may also 
cause tuberculosis, but it is less frequent. The second group is Mycobacterium leprae, causing 
leprosy. The final, third group are non-tuberculous mycobacteria which includes all the other 
mycobacteria that can cause clinical manifestations similar to those of tuberculosis. Most non-
tuberculous mycobacteria are not spread by airborne means from person to person and do not 
cause clinically significant diseases in immunocompetent people (4).  
 
1.4. Epidemiology 
 
As much as 1.4 million tuberculosis deaths were recorded in 2015, and an additional 
0.4 million deaths resulting from TB disease among people living with HIV (By the 
International Classification of Diseases system it is specified that when a HIV-positive person 
dies from TB disease, the underlying cause is classified as HIV and not TB) (5).  
 
Alongside HIV, tuberculosis is the second main cause of death from an infectious 
disease and one of the major public health threats. Most of the deaths (95%) occur in the 
developing, low-income countries. Every year over 100,000 children die due to tuberculosis 
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in these countries (4). According to the World Health Organization, most cases are estimated 
to be in Asia and Africa, with the highest incidence in India (6). 
 
1.5. Transmission 
 
As already mentioned above, the spread of Mycobacterium tuberculosis occurs 
predominantly through the air. Humans are the only reservoir for these bacteria and when an 
infected person coughs, sneezes, or speaks near another person, they inhale the droplet nuclei 
and person-to-person spread occurs. There may be as many as 3000 infectious nuclei per 
cough (1). Those infected nuclei can remain in the air for some time. It is believed that people 
that were in the close contact with the infected individual have higher chances of being 
infected. On the other hand, it is still not completely understood why some people infected 
with Mycobacterium tuberculosis never develop the disease, but some do. 
 
1.6. Pathogenesis 
 
Primary tuberculosis is the first infection with Mycobacteria tuberculosis. Once the 
person inhales the organism, it gains entry to the lungs, more specifically to alveoli. Host's 
innate responses react immediately and activate the alveolar macrophages to ingest and 
destroy the bacilli. The bacteria then are trapped in macrophages, which do not manage to 
effect successful counteraction, and in that case, the bacteria continue to survive in the 
macrophages and starts to multiply and grow. If the growth and replication of bacilli are 
successful, macrophage will eventually rupture and bacilli will be released. Other phagocytes 
are then activated to control the infection by ingesting ruptured phagocytes and their spread 
content. They become infected themselves, and in this way, the infection is expanding 
through the lungs. This process induces chronic inflammatory response and formation of 
granulomas that contain clusters of macrophages, epithelioid cells, giant cells and 
lymphocytes. Over some time, the centres of granulomas become necrotic, resembling soft 
cheese- a phenomenon called caseous necrosis. Caseating granulomas are the hallmark lesions 
of tuberculosis and are rarely seen in other diseases. Other features of tuberculosis infection 
are also fever, night sweats and weight loss caused by production and activation of different 
cytokines, including interleukin 1 and tumour necrosis factor (7).  
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After the initial contact with the infection, only a fraction of people develops an active 
disease. In the majority of people, the immune system manages to control the infection and 
the patient develops cell-mediated immune memory to the bacteria. This is termed the latent 
tuberculosis (8).  
 
1.7. Clinical manifestations  
 
Tuberculosis can be classified as pulmonary, extrapulmonary or combined. Pulmonary 
tuberculosis can be further divided into primary disease or post primary disease. 
1.7.1 Pulmonary tuberculosis  
1.7.1.1 Primary disease  
After the inhalation of M. tuberculosis for the first time, primary disease develops. It 
commonly occurs in infants, children, and immunosuppressed adults. Some people remain 
asymptomatic after the primary exposure to tubercle bacilli and in some people flu-like 
symptoms develop- usually cough, fever and chest pain. Characteristic lesions called Ghon 
focus also develop at this time of first exposure and usually heal spontaneously. A Ghon 
lesion together with hilar adenopathy is called a Ranke complex (9). With correct treatment, 
the disease is under the control and there is no symptoms or signs of the disease. The problem 
is that it is not possible to eliminate all the bacilli from the body and they can remain silently 
in the body for years, or even decades. For as long as the person is immunocompetent, there 
will be no clinical signs of the disease. In the case of the disease that suppresses the cell- 
mediated immunity, M. tuberculosis may reactivate and grow, divide and cause post primary, 
or so-called secondary symptomatic disease.  
In immunocompromised people, young children or old patients with other 
comorbidities those lesions may persist and the disease will rapidly progress to clinical 
illness. The initial lesion increases in size, pleural effusion develops due to penetration of 
bacilli into the pleural space and in the most severe cases, the central portion undergoes 
necrosis, and cavitation develops. Sometimes the bacilli enter the lymphatic system and cause 
hilar or paratracheal lymphadenopathy. Those enlarged lymph nodes may compress bronchi 
and cause partial obstruction of airways (1).  
Hematogenous dissemination can follow primary infection. In some individuals, 
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immune response fails or is not robust enough to fight against the infection and miliary 
tuberculosis develops.  
1.7.1.2. Posts primary disease  
Post primary disease can be also called secondary, adult-type or reactivation disease. It 
is actually the reactivation of the tuberculosis after the primary disease and does not occur in 
all patients. It is caused by bacilli that survived in the primary lesions. They favour well-
oxygenated places to grow, so usually the most affected are upper lobes of the lungs (mostly 
apex), where the oxygen content is the highest. At the beginning, secondary infection is 
mainly asymptomatic and if it is not treated on the time, the disease will silently progress and 
worsen. Post primary disease is characterized by chronic tissue lesions, cavity formation and 
satellite lesions. Cavities contain high number of organisms- between 109 and 1010 organisms 
and people with cavitary disease individuals are highly infectious (9).  
Symptoms that develop during this stage of the disease are weight loss, fever, night 
sweats and cough. At the beginning, they might be non-specific. Cough may be non-
productive or productive, containing the mucous, pus or blood. It may present also with the 
massive haemoptysis. In this case, patient has most probably far-advanced lesions. In some 
cases finger clubbing may develop (10). 
1.7.2. Extrapulmonary tuberculosis   
There are many different presentations of extrapulmonary tuberculosis, but the most 
common is lymph node tuberculosis. Other types are pleural tuberculosis, skeletal 
tuberculosis, genitourinary tuberculosis, gastrointestinal tuberculosis, pericardial tuberculosis, 
central nervous system tuberculosis, HIV associated tuberculosis and miliary tuberculosis.  
1.7.2.1. Lymph node tuberculosis 
Lymph node tuberculosis or so-called tuberculous lymphadenitis is most common 
presentation of extrapulmonary tuberculosis in both HIV- negative and HIV- positive 
patients. It accounts for 35% of all cases worldwide and is especially common in HIV- 
infected patients (1). In the past, the main pathogen causing tuberculous lymphadenitis was 
M. bovis, but recently it is mainly caused by M. tuberculosis. Patients usually present with 
enlarged lymph nodes, usually in cervical regions (in the past cervical lymphadenitis was 
called scrofula), even though other regions can be also affected. Diagnosis is usually 
confirmed by lymph node biopsy and microbiological examination (10). 
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1.7.2.2. Miliary tuberculosis 
Miliary tuberculosis or so-called disseminated tuberculosis occurs because of 
hematogenous spread of tubercle bacilli. Genevan physician and writer John Jacobus Manget 
was the first person using the term miliary tuberculosis. In 1700s he found many small white 
nodules in the lungs of the patients with disseminated tuberculosis that resemble millet  
seeds (11).  
Miliary tuberculosis can develop from a progressive form of primary disease or can be 
a product of reactivating disease. In some individuals, the immune system is not strong 
enough and fails to protect the body from infection (10). People with the great risk of getting 
miliary tuberculosis are individuals with the weakened immune system or very young or old 
people. The risk of dissemination is determined mainly by mycobacterial virulence factors 
and host immune defences. Furthermore, studies showed that 30% to 80% of patients with 
miliary tuberculosis had some underlying medical conditions as concurrent childhood 
infections (measles, tonsillitis), malnutrition, HIV/AIDS, gastrectomy, alcohol abuse, 
malignancy, corticosteroids or other iatrogenic immunosuppression, connective tissue 
disorders (with or without iatrogenic immunosuppression), end-stage renal disease, diabetes 
mellitus, solid organ or bone marrow transplantation, silicosis and pregnancy (11).  
Clinical presentation is non-specific. Patients usually present with night sweats, 
weight loss, nausea, fatigue, low-grade fever, abdominal pain and cough. During the physical 
examination of the abdomen, usually nothing is obtained, but sometimes hepatomegaly, 
splenomegaly as well as lymphadenopathy can be found. During the eye examination, the 
choroidal tubercles can be found. They are characteristic for miliary tuberculosis in up to 30% 
of cases (1). In two thirds of patients, multiple small white nodules (0.5 to 1 mm in diameter) 
are seen on the chest radiograph. If it is negative and there is no nodules seen, diagnosis of 
tuberculosis should not be excluded- especially in old and immunocompromised (HIV- 
positive) people (9). The biggest problem with military tuberculosis is to diagnose it on time. 
There are no specific markers for disseminated tuberculosis and findings are as already 
mentioned- nonspecific. If it is not diagnosed and treated on the time, it can be rapidly fatal.  
1.7.2.3. HIV associated tuberculosis 
Most powerful known risk factor predisposing people to tuberculosis infection is 
human immunodeficiency virus (HIV) (12). Tuberculosis is responsible for 24% of all HIV-
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related mortality, making it the most common cause of death among people with HIV 
infection (1).  
HIV positive patients are at an increased risk for developing tuberculosis disease from 
the recent infection. HIV also speeds up the reactivation of latent infection and accelerates the 
progression. On the other hand, tuberculosis also expedites the progression of the HIV 
infection. It is recommended for all HIV positive patients to be screened for both- active and 
latent tuberculosis. HIV infected patients with tuberculosis usually present with minimal 
symptoms or even without them. It is also common for those patients to present with 
extrapulmonary tuberculosis, which makes establishing the diagnosis even more difficult 
(13).  
1.7.3 Latent tuberculosis 
People being infected with Mycobacteria tuberculosis may develop cell mediated 
immune memory to this bacterium. People with latent tuberculosis are neither contagious, 
neither symptomatic (8). It is believed that one third of the whole population has latent 
tuberculosis (10). Unfortunately, it is not possible to predict who will develop an active 
(contagious and symptomatic) tuberculosis and who will remain with latency. Latent 
diagnosis can be diagnosed with the tuberculin skin test and chemoprophylaxis can be given 
to these individuals in the form of isoniazid, administered for six to nine months (14).  
 
1.8. Diagnosis of tuberculosis 
 
The diagnosis of tuberculosis begins with the clinical suspicion. Medical history 
should also be obtained. On the x-ray, upper lobe cavitation may be seen. Doctor should also 
check for general symptoms of tuberculosis, as enlarged lymph nodes, fever, nausea, fatigue, 
anorexia with weight loss, hemoptysis and cough that may be productive or nonproductive. 
None of those symptoms is specific, so other conditions such as malignancy should be 
excluded. In patients with weakened immune system, finding on the chest radiograph can be 
non-specific, for example lower lobe cavitations can be found. Computerized tomography is 
also an important tool in the detection of tuberculosis. It shows the extent and the progression 
of the disease and involvement of the lymph nodes and organs.  
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Specimens that can be taken for establishing the diagnosis of tuberculosis can be from 
different sites. Most common they consist of fresh sputum, gastric washings, urine, pleural 
fluid, cerebrospinal fluid, joint fluid, biopsy material or blood. All the specimens that are not 
sterile need to be liquefied with N-acetyl-L-cysteine–NaOH digestion-decontamination 
method with which other bacteria are being killed. This procedure is not needed for sterile 
fluid specimens that can be directly examined and cultured (3).  
1.8.1. Sputum smear microscopy 
Examination of the sputum is one of the oldest and one of the most important methods 
in diagnosis of active tuberculosis. The sputum is examined under the microscope for acid-
fast bacilli by staining. Fluorescence microscopy with auramine-rhodamine stain is more 
sensitive than traditional acid-fast stains, such as Ziehl-Neelsen, and is the preferred method 
for clinical material (3).  
Ziehl-Neelsen is the common stain for light microscopy and even though it is not the 
best test available on the market, it is still commonly used in practice. It is inexpensive and 
easily available. The main problem is its sensitivity that requires 5.000 - 10.000 bacilli per 
milliliter of sputum (15).  
Three sputum smears are recommended. Negative smears do not definitely exclude the 
infection, but if acid-fast organisms are found in the specimen, this is the evidence of 
mycobacterial infection.  
1.8.2. Culture of Mycobacterium tuberculosis complex  
Culture remains the most accurate and sensitive test for diagnosing tuberculosis. 
Positive culture is needed for diagnosis, but negative results do not rule it out. The main 
problem with culturing the M. tuberculosis is its slow growth. It growths very slowly, so 4-8 
weeks are usually needed to detect the growth (1). Culturing multiple samples has higher 
sensitivity than culturing only one specimen does. In adults, the first culture detects 85,8% of 
cases confirmed to have M. tuberculosis, the second culture adds a further 11,9% and the 
third specimen 2.3% with subsequent cultures adding smaller numbers (16).  
There are several methods of culturing that can be used: solid, liquid, commercial, or 
non-commercial media. Most commonly used is egg- based non-commercial Lowenstein–
Jensen medium. The main disadvantage of the culturing is that it is time consuming. As 
mentioned before, tubercle bacilli are not fast growers, it takes a lot of time to see the results, 
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and during this time, the disease is worsening and progressing.  
1.8.3. Drug- susceptibility testing  
For all patients, the isolate should be tested for susceptibility to isoniazid and 
rifampicin to see if there is any drug resistance. Patients that are resistant to any of the 
standard treatment will not react to those drugs and will need some other medications. Further 
susceptibility testing for second-line anti-tuberculosis drugs-especially the fluoroquinolones is 
mandatory (1).  
1.8.4. Detection of the DNA 
Nucleic acid amplification techniques such as the polymerase chain reaction (PCR) 
offer the rapid detection of M. tuberculosis in clinical specimens. Those tests have high 
sensitivity (55% to 90%) and specificity (about 99%) and are used mainly for rapid 
confirmation of tuberculosis (3). The main disadvantage is that those assays are expensive, 
not easily available and therefore not widely used.  
1.8.5. Serological tests 
There are many serological tests available on the market, but tests showed, that they 
have low sensitivity and specificity and are therefore of no clinical value (1). 
1.8.6. Tuberculin skin testing for diagnosis of latent M. tuberculosis infection  
 This test is most commonly used for screening for latent tuberculosis infection. It is 
also called Mantoux test or PPD test (purified protein derivative test). It is recommended and 
given only for the patients in the high-risk group, such as recent (<5 years) immigrants from 
developing countries, healthcare workers, prisoners, alcoholics, chronic prednisone users (>15 
mg/day), close contacts of those with tuberculosis and HIV-positive persons (17).  
 Five tuberculin units (antigens) is injected intradermal –usually in the forearm. 
Reaction should be read 48 to 72 hours after injection. Only the degree of induration (raised 
area) should be measured in millimetres for a positive Mantoux test result. Erythema does not 
count and should not be obtained and measured.  
Tuberculin skin test interpretation depends on two factors: person’s risk of being 
affected and measurements of induration in millimetres (18).  
 If there is no induration, the result is 0 mm and the test is marked as negative. 5 mm 
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induration size indicates positive latent tuberculosis result for HIV positive patients, chronic 
prednisone (steroid) users, patients with abnormal x-rays that are consistent with old 
granulomas and patients that are in close contact with people with tuberculosis (health care 
workers excluded). 10 mm induration size indicates positive test for HIV positive workers, 
chronic steroid users and people with abnormal x-ray consistent with old granulomas. 15 mm 
or more of measured induration size is positive in people with no known risk factor for 
tuberculosis (17).  
False- negative reactions commonly occur in immunosuppressed patients and false-
positive reactions can be due to previous BCG vaccination, infection with non - tuberculous 
mycobacteria or wrong interpretation of reaction (1).  
Sometimes if the result is false negative and you suspect so, two-stage PPD can be 
done. Usually the second test is done one week after the first one. If it is negative, you 
exclude the diagnosis of latent tuberculosis and if it is reactive (>10 mm) it is true positive. It 
is important to know that with the repeated testing person cannot become positive, if she was 
PPD-negative before (19). 
 Tuberculin test should not be used during the active tuberculosis due to its low 
sensitivity, specificity and inability to distinguish between the active and latent tuberculosis. 
The only contraindication is previous severe reaction to tuberculin skin test.  
1.8.7. Interferon - gamma release assay (IGRA) 
IGRA measures T cell release of IFN-y in response to stimulation with specific 
tuberculosis antigen. Two highly specific antigens are available on the market: ESAT-6 and 
CFP-IO (1). IGRA is not able to distinguish between the active and latent tuberculosis and 
should be used to screen asymptomatic patients with the risk of tuberculosis infection. 
Specificity and price are higher compare with the tuberculin skin test, but the sensitivity is 
similar. There is no cross-reaction with BCG vaccination and the previous vaccination with 
BCG vaccine will not make IGRA positive (17).  
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1.9. Prevention 
 
Prevention is the key in stopping the transmission of tuberculosis. The best way to 
stop the transmission is an early detection and treatment of active tuberculosis. During the 
active state of the disease, the person is highly contagious and with the proper and effective 
treatment, the transmission can be significantly reduced. Another goal is prevention of active 
disease in the people with known latent tuberculosis and prevention of infection in high-risk 
group people. The vaccination with the only vaccine currently available – BCG vaccine is 
another important strategy.  
1.9.1. BCG vaccine  
BCG (Bacille Calmette-Guérin) is the only licensed vaccine for tuberculosis. It is a 
live attenuated vaccine derived from M. bovis. In babies it reduces the risk of disseminated 
and central nervous system tuberculosis, but its efficiency in adults is very variable (8).  
In most high-income countries, where the incidence of the tuberculosis is low, only 
newborns being in the high - risk group for getting tuberculosis are vaccinated. In the 
countries where the incidence of the tuberculosis is still high (mostly low-income countries) 
the vaccination with the BCG vaccine at birth is still routinely recommended. It is 
contraindicated to vaccinate HIV positive children (20).  
 
BCG vaccine is relatively safe and serious complications are very rare. Three weeks 
after the vaccination erythemous macula appears and slowly transforms into the scar during 
following three months. Most common side effects are ulceration at the vaccination site and 
regional lymphadenitis. Those are localized and usually self - limited complications. Most 
serious, but luckily very rare complication is disseminated infection that occurs in ten cases 
per ten million doses administered. Usually it occurs in immunocompromised people and is 
commonly fatal (1, 21). 
 
1.10. Treatment  
	
1.10.1. Treatment of drug susceptible tuberculosis  
As mentioned above, mycobacteria grow very slowly and they are resistant to most 
antibiotics. It is also well known, that those species have an ability to develop new forms of 
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resistance. They can be even completely resistant to many drugs. The wall of Mycobacteria is 
rich in lipids and functions as a permeability barrier and is therefore hardly permeable or even 
impermeable to many agents. (22). Mycobacterial species are also intracellular pathogens and 
therefore inaccessible for drugs that penetrate these cells poorly. Because of all those reasons 
long treatment with different kind of drugs is required to overcome the infection (22). Goals 
of the treatment are elimination of the symptoms, prevention of relapses and transmission and 
better quality of life. Treatment for all forms of drug susceptible tuberculosis is divided into 
two crucial phases: initial or bactericidal and continuation or sterilizing phase. With this 
regimen, more than 90% of people infected with tuberculosis can be cured (1).  
During the initial phase the patients receives a standard combination of four major 
drugs that are considered first- line agents for the treatment of tuberculosis: rifampicin, 
isoniazid, pyrazinamide and ethambutol. Treatment with only one drug can lead to bacterial 
resistance, requiring four drugs use. Those drugs together should be taken for eight weeks. 
Daily dosages for person with 50 kilograms or more are rifampicin 600mg, isoniazid 300mg, 
pyrazinamide 2g and ethambutol 15mg/kg (23). 
Isoniazid has the bactericidal activity and it inhibits synthesis of mycolic acids, one of 
the essential component of mycobacterial cell wall. It is the most active drug from the 
treatment scheme. It is toxic to liver and it is its most common side effect. During the 
treatment with isoniazid, liver enzymes should be checked and followed-up. If only minor 
increase of liver enzyme occurs, treatment can be continued, but in the case of potentially 
lethal isoniazid-induced hepatitis, treatment should be immediately stopped. The main 
symptoms of isoniazid- induced hepatitis are jaundice, loss of appetite, vomiting and pain in 
the right upper quadrant. Another side effect of the isoniazid can be peripheral neuropathy. To 
prevent it, pyridoxine should be given with isoniazid (22).  
Rifampicin also has bactericidal activity and it inhibits the RNA synthesis. Probably 
the most shocking side effect of rifampicin for patients is that it stains body fluids into the 
orange colour. Other side effects can be rash, nephritis, thrombocytopenia, cholestasis and 
flu-like syndrome. (22).  
Ethambutol obstructs the formation of the cell wall and therefore has bacteriostatic 
activity against susceptible mycobacteria. Its most common adverse effect is optic retrobulbar 
neuritis (8).  
	 17	
Pyrazinamide is another drug with bacteriostatic activity used for treatment of drug-
susceptible tuberculosis. Unfortunately, its mechanism of action is not completely understood. 
It is believed that under acidic conditions pyrazinamide is converted into the active pyrazinoic 
acid that disturbs transport functions of the cell membrane. Its most dangerous side effect is 
hepatotoxicity, but it can also cause hyperuricemia, acute gout and nausea. (22). 
Since all of those drugs in some extent cause liver toxicity, liver enzymes should be 
carefully monitored. If hepatotoxicity occurs and those drugs cannot be tolerated well, 
changing the treatment regimen should be considered. Fluoroquinolones are excreted via the 
kidneys therefore causing less damage to the liver. During initial phase the goal is to kill the 
majority of bacilli, prevent further transmission of the disease and prevent the emergence of 
drug resistance (1,10). 
During the second, continuation phase patient should stop taking pyrazinamide and 
ethambutol, but continue with isoniazid and rifampicin at the same doses for another four 
months. These two drugs will eliminate the persisting Mycobacteria. It is important to tell the 
patient that disappearing of symptoms does not mean that the disease is gone and that he or 
she should not stop taking medications when symptoms are gone and person feels better. If 
the treatment is not completed it means that there are still alive bacteria in the body and 
relapse will occur- commonly with drug-resistant disease (22, 23).  
1.10.2. Treatment of drug resistant tuberculosis  
Drug-resistant tuberculosis can be primary or acquired. When patient is infected from 
the start with the stain that is drug resistant, we are talking about primary drug resistance. 
Acquired resistance on the other hand usually develops because of inappropriate treatment 
regimen - monotherapy (1). The incidence of drug resistant tuberculosis is increasing and it is 
estimated that around 8% cases of Mycobacteria tuberculosis nowadays are resistant to 
isoniazid (10). By WHO definition, multi –drug resistant tuberculosis is caused by bacteria 
that do not respond to, at least, isoniazid and rifampicin, the two most powerful anti- TB 
medicines. Those types of tuberculosis that are resistant to either isoniazid or rifampicin or 
both of them, require different kind of treatment than susceptible strains of tuberculosis. They 
are treated with second line treatment regimens. When tuberculosis is additionally resistant 
even to fluoroquinolone and second line injectable drugs, we are talking about extensively 
resistant multi – drug tuberculosis (24).  
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Drug resistant tuberculosis should be treated with at least four drugs to which 
organism is likely to be susceptible. Drugs are chosen from the five groups based on efficacy, 
safety and cost. First group of drugs are first- line drugs in the treatment of tuberculosis: 
isoniazid, pyrazinamide, and ethambutol. If the stain is susceptible to any of those drugs, that 
drug should not be stopped. High dose should be given and drugs should be taken orally. 
Second groups are fluoroquinolones and if possible, levofloxacin or moxifloxacin should be 
used. In the third group are the injectable drugs, which should be used in the following order: 
capreomycin, kanamycin, and then amikacin. If susceptibility is suspected, at least one of the 
drug from this group should be always used. In the group four there are second-line drugs and 
should be used in the following order: thioamides, cycloserine and then aminosalicylic acid. 
In the last, fifth group there are agents which role is not well understood in the treatment of 
tuberculosis: clofazimine, amoxicillin with clavulanate, linezolid, carbapenems, 
thioacetazone, and then clarithromycin (25). 
WHO does not recommend using the drugs from the fifth group routinely. Those 
drugs should be used only when adequate regimen with the medications from the group one to 
four cannot be made. Usually they are used in extensively resistant multi – drug tuberculosis.  
 
1.11 Genetics of respiratory infections  
 
It is known that individual responses to different respiratory diseases vary and depend 
on the host genetics profile. A lot of research studies about the genetics of respiratory 
infections have been done and most of them show unclear results.  
 In 2015, a systematic review and meta- analysis of 386 studies, out of 24,823 studies 
from for bibliographic databases was made (26). This extensive study was looking for host 
genetic factors in different infections- tuberculosis, influenza, respiratory syncytial virus, 
SARS-Coronavirus and pneumonia. Majority of the points extracted from this research were 
connected to tuberculosis. In total, they found one single-nucleotide polymorphism from IL4 
gene for all respiratory infections, and role of TLR2 gene and CCL2 gene in tuberculosis (26). 
The study of Patarčić et al. also identified other previous studies that suggested 
various genetic backgrounds in the definition of the tuberculosis risk. However these studies 
mainly failed in numerous aspects. Most commonly these studies were underpowered to 
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detect a true effect, they had problems in diagnosis and case definition, but even data analysis 
and reporting, meaning that the entire field of research had suffered from substantial 
methodological problems (26).  
Based on the inconsistent findings of previous studies and the fact that the exact 
correlation between the genetic background and tuberculosis is still not proven, future 
investigation is needed in order to show a possible connection.  
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2. OBJECTIVES 
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The main objective of this study was to investigate the genetic factors and their ability 
to be used as the predictor for development of tuberculosis. 
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3. MATERIALS AND METHODS 
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This study was based on the data gathered on the sample of the 10,001 Dalmatians 
biobank (Figure 1).   The main objective of this program is to create a comprehensive 
resource for the study of genetic, environmental and social determinants of health and 
diseases with emphasis on chronic diseases, which are the leading cause of death in Croatia 
and other developed countries (27). The main approach of this method is the analysis of the 
association of a large number of genetic markers with the observed trait (28).  
The postal invitations were sent to all adult island inhabitants (aged 18 or more years), 
inviting them to participate in health examinations free of charge, during which time they 
would also participate in the research study that aimed to collect relevant information on the 
island inhabitants and develop a biobank. The efforts to include additional subjects were 
supplemented by the appearance in the local newspapers, radio stations and through contact 
with the local physicians, who were also encouraged to promote the idea of participation in 
their registered subjects. The target sample size was about 1,000 subjects, and this target 
sample size was reached after only five weeks of the field work.  
 
All of the subjects were firstly informed about the study, its goals, methodology, 
content and risks, and were provided an opportunity to decide if they would like to 
participate. After decision, they were then read the informed consent, to which they could 
have responded positively or they could have also rejected it (a total of two people have 
rejected participation after all the relevant information was relayed on to them). The approval 
for this study was issued by the Ethical board of the Medical School of Zagreb and the Multi 
Ethics Research Committee from Scotland. 
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Figure 1. The map of the 10,001 Dalmatians project sites 
 
For purpose of this study, we took the data from the Vis island sub-sample, where we 
had encountered the most cases of tuberculosis, therefore aiming to maximize the chances of 
the detection and reducing the extent of possible between-island diversity of genetic 
background. We used the medical records as the source of information on tuberculosis (TB). 
Any hospital admission was therefore considered as a positive TB diagnosis, while subjects 
who did not have TB-related hospital admission were considered as controls.  
For purposes of the DNA extraction, we used a peripheral blood sample, with DNA 
extraction process completed by the Tepnel Nucleon kit (UK). After extraction, Helmholtz 
Centre for genotyping was used to perform genotyping, with Illumina HumanHap 300 
platform, with 317,058 genetic markers in the analysis. We then used genome-wide 
association analysis to discover candidate genes implied in the tuberculosis diagnosis. The 
target variable was used in the binary form (positive TB in medical history or control), with 
additional adjustment for age and sex effects, as well as the familial relatedness (due to 
extensive pedigree structure in the investigated population). All analysis were performed 
using R package (http://www.r-project.org), with significance set at P<4*10-8 due to multiple 
testing.  
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4. RESULTS 
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We analysed the data for 924 subjects, with 536 men (58.0%) and overall median age 
of 57 years (range 18-93 years). Median age for men was 56 (18-87), while for women 
median age was 52 (18-93), without significant difference (P=0.429).We have recorded 
median years of schooling of 11.0 (with a range of 1-20), and assessed the median 
socioeconomic status as 9.0 (range 0-16). We have recorded 28 tuberculosis cases (3.0%), 
most commonly being diagnosed during childhood of the elderly subjects. We had more 
detailed information for 22 cases, with the average age of acquiring TB being 25.0±9.9 years. 
In addition, seven cases had another infectious disease record in their hospital admission 
medical history (25.0%), most commonly pneumonia or severe sinusitis cases. This suggest a 
significant overrepresentation of the coinfection under the assumption that such coinfection 
rates are very rare (P<0.001 for 2% expected coinfection rates), rare (P=0.008 for 10% 
coinfection rates) and holds up significance all the way up to coinfection rate of 12.6% 
(P=0.048). Co-occurrence of TB and asthma or severe allergy also showed an interesting 
pattern, with four recorded cases (14.3%).  
 
The genome-wide association analysis had suggested three significant results (Table 
1), out of which there was one gene involved in the TB prediction. This was a CECR6 gene, 
located at chromosome 22 (Table 1). Other than this results that had reached formal 
significance level, there were three more genes that were having suggestive P values – 
DSCAM, FOXK2 and KLF8 (Table 1, Figure 2).  
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Table 1. Genome-wide association analysis results 
rs Chromosome 
Effect 
allele 
Minor 
allele 
frequency N 
BET
A P Gene 
rs10515081 5 A 3% 917 0.09 4.96E-10 NA 
rs3924359 16 A 6% 914 0.07 3.44E-09 LOC105371275 
rs971768 22 A 7% 917 0.06 1.38E-08 CECR6 
rs5953425 X G 19% 902 0.03 2.94E-07 NA 
rs17687319 6 G 9% 917 0.05 8.48E-07 NA 
rs2911730 8 G 9% 917 0.04 2.19E-06 NA 
rs6504989 17 G 13% 917 0.04 2.37E-06 NA 
rs10057220 5 A 10% 917 0.04 2.46E-06 NA 
rs11909247 21 G 5% 917 0.06 2.84E-06 DSCAM 
rs3794716 17 A 6% 917 0.05 5.45E-06 FOXK2 
rs16999738 21 A 3% 916 0.07 8.97E-06 DSCAM 
rs4982925 14 A 5% 917 0.05 9.16E-06 LOC101927045 
rs1869288 2 G 12% 917 0.03 1.04E-05 NA 
rs13011060 2 A 22% 917 0.03 1.14E-05 LOC101928278 
rs9320845 6 A 9% 911 0.04 1.21E-05 LOC105377979 
rs3922927 X A 6% 917 0.04 1.25E-05 KLF8 
rs16940235 15 C 4% 917 0.06 1.38E-05 LOC105370956 
rs1034442 6 A 9% 917 0.04 1.47E-05 LOC105377978 
rs1919870 6 A 9% 915 0.04 1.50E-05 LOC105377979 
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Figure 2. Manhattan plot of the TB GWAS in the island of Vis sample from the 10,001 Dalmatians project 
 
 
Figure 3. BioCarta pathway involving CECR6 gene 
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Figure 4. Gene ontology network of CECR6 gene 
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5. DISCUSSION 
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The results of this study are showing a significant relationship of the CECR6 gene 
with an individual tuberculosis risk. This is the first mention of the relationship of this gene 
with TB in research papers, although some previous studies have implied a role of this gene in 
an individual infection response (29).  
 In addition, GWASdb disease associations option suggests that this gene is likely 
implied in human immunodeficiency virus infection disease (risk score of 0.746), viral 
infections (0.228), other infectious agent disease (0.145) or immune system disease (0.055) 
(30), providing further support to the hypothesis that this is a causal gene for tuberculosis 
pathogenesis.  
 The development of the gene network suggests that this gene is linked to TNF/stress 
related signalling, AKT signalling pathway implied in survival and response to extracellular 
signals and ATM signalling pathway involved in major events in the cell (Figure 3).  All these 
pathways point towards an important role of this gene in the cellular stress response, 
including that in CBL mediated downregulation, which has previously been implied in 
cancer, thus providing a possible explanation for a frequent co-occurrence of TB with cancer 
(31).  
Analysis of the Gene Ontology database indicated a role of this gene in synaptic 
processes, but also in phagocytosis, further supporting possible role of this gene in TB 
pathogenesis (Figure 4).  
Other functions of the gene include Cat eye syndrome, involved in various extent of 
defects of the iris of the eye, which usually comes in combination with various other 
morphologic disturbances and malformations, including anal atresia, preauricular 
deformations, cardiac defects, kidney problems, short stature and scoliosis (32).  
Most notably, there is a single claim that links the CECR6 gene to tuberculosis, as a 
part of the patent US 20140080732 A1, where CECR6 is listed as one of the genes that were 
implied in the tuberculosis development (33).  
However, this gene is very close to the IL17RA gene, which has previously been 
implied in tuberculosis pathogenesis in numerous studies (34, 35). Therefore, it might simply 
be a reflection of the proximity of these two genes, therefore requiring a dedicated sequencing 
and follow-up study to clearly separate between the functions of these two genes and creating 
an opportunity to establish a causal association of the gene with tuberculosis risk. All these 
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sources indicate that the mutation in this gene are associated with the protective effect, 
possibly by interfering with the mechanisms of the Mycobacterium entry into the cell (36).  
There were three more suggestive genes found in this study - DSCAM, FOXK2 and 
KLF8. DSCAM was previously implied in HIV risk determination (37), but also stress 
response (38). FOXK2 has been described to have an IL2 enhancing/promoting function, 
further supporting the plausibility of the involvement in the tuberculosis pathogenesis (39).  
Lastly, KLF8 was implied as a transcription factor, involved in numerous activities in 
relation to cell cycle (40). When taken together, these results suggest a complex genetic 
background underlying tuberculosis pathogenesis. This is further implicated in frequent co-
infections with other infectious disease, further pointing towards a common pathway in 
affected individuals that makes them more susceptible to various infections.  
Interestingly, mean age of tuberculosis development and hospital admission in this 
study was early on in adulthood, as opposed to the expected later life occurrence. This could 
either be a consequence of elderly people not participating in the study (selection bias), or 
simply lack of reliable medical records (information bias). There appears no support for the 
population-specific sub-structuring, which is another mechanism that can affect the results. It 
arises as the consequence of hidden genetic clusters in a population, but previous studies have 
shown a high level of population genetics homogeneity on the islands, therefore negating this 
hypothesis (41).  
The limitations of this study include the use of a single population and lack of any 
kind of replication. In addition, as the study was performed in an island population, these 
results could be population-specific, especially having in mind a long-lasting co-evolution of 
TB with humans, and possibly pointing towards a population-specific ways of handling a 
strong selective pressure, such as TB.  
 All the above claims clearly point towards a role of the CECR6 gene in 
tuberculosis pathogenesis, and most likely involving phagocytosis mechanisms. Based on 
these results and after an un-linked replication, this gene could indeed become one of the 
biomarkers and elements used to assess and predict an individual tuberculosis prediction.  
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6. CONCLUSIONS 
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The results of this study suggest that CECR6 gene may have a role in tuberculosis 
pathogenesis. The biological function of the gene is in line with this claim, as it has been 
implied in several processes that might related to tuberculosis. Three additional genes, which 
did not reach formal statistical significance (DSCAM, FOXK2 and KLF8) also, seem to have 
roles that might easily be related to tuberculosis pathogenesis. Finally, all four of reported 
genes are in close proximities to genes of established roles in the immune system function, 
possibly reflecting their physical linkage.  
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8. SUMMARY IN ENGLISH  
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Host genetics in tuberculosis susceptibility 
Objectives: The aim of this study was to investigate the genetic background underlying 
increased risk of developing tuberculosis.  
Methods: A subset of the 10,001 Dalmatians study data were used for purpose of this study. 
We performed a genome-wide association analysis of the subjects who had a medical record 
of hospital admission due to tuberculosis. All other subjects who were not admitted to 
hospital for tuberculosis treatment were considered as controls.  
Results: A single significant result (at the formal significance level cut-off value of 3*E-08), 
belonging to the CECR6 gene was recorded. Additionally, DSCAM, FOXK2 and KLF8 
yielded nearly significant result, supporting the previous idea of complex genetic background 
risk definition.  
Discussion: This is the first report of the CECR6 gene in tuberculosis pathogenesis, which is 
in line with the biological functions previously described for this gene. The additional three 
genes also seem to have roles that can easily be associated with tuberculosis. The genetic 
architecture underlying tuberculosis seems to be very complex, and requires larger-scale 
analyses in order to be able to develop a diagnostic tools and provide individualized 
prevention measures in the future, by focusing on individuals that have the highest underlying 
risk for contracting and developing clinically relevant disease.  
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9. SUMMARY IN CROATIAN  
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Genetika domaćina u osjetljivosti na tuberkulozu 
 
Cilj: Istražiti genetsku podlogu domaćina kao čimbenika rizika za nastanak tuberkuloze.  
Metode: Koristili smo podatke iz projekta 10.001 Dalmatinac, I to populacije otoka Visa, u 
kojoj smo zabilježili najveći broj slučajeva tuberkuloze. Ispitanici bez podatka o bolničkom 
liječenju smatrani su kontrolama.   
Rezultati: Rezultati su ukazali na ulogu CECR6 gena u nastanku tuberkuloze, što je novi 
genetski mehanizam koji predviđa individualni rizik nastanka tuberkuloze. Još tri gena su bili 
sugestivni, potvrđujući složenu situaciju I otežano predviđanje ishoda bolesti.  
Zaključak: Iako smo opisali novi genetski mehanizam, rezultati ukazuju na veliki opseg 
varijabilnosti u određivanju osobnog rizika, koji je potencijalno dodatno kompliciran 
mogućim lokalnim rezultatima ko-evolucije patogena i domaćina. Okrupnjavanje 
istraživačkih pokušaja I stvaranje konzorcija će omogućiti detaljniji uvid I osigurati uvjete za 
razvoj individualiziranog pristupa predviđanju pojave bolesti.  
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